International cooperation
our competitive advantages
Original and in-demand portfolio of innovative products; patents for new molecules and pharmaceutical manufacturing technologies in Russia and abroad
High-tech biotechnological full-cycle manufacturing in compliance with the EAEU and EU GMP standards: from the synthesis of the APIs to the release of FDF
R&D investment program and conducting international multicenter clinical trials of original products
Experience in implementing international projects in the production and R&D fields in cooperation with Big Pharma companies: Pfizer, Abbott, Boehringer Ingelheim, ISU Abxis
Abbott
2008pioneering biopharmaceutical collaboration in Russia
Petrovax partnered with Abbott to establish a biotechnology project focused on producing immunobiological drugs. In 2008, a pharmaceutical complex was launched in the Moscow Region, marking the first-ever production in Russia of the influenza vaccine Grippol® Plus in single-use syringes without preservatives. It is one of the most exported influenza vaccines in Russia1 and is part of the state immunization programs of several countries.
Pfizer
2014first import substitution project for high-tech vaccines in Russia
Together with Pfizer, Petrovax implemented full-cycle technology for the local production of the 13-valent conjugate pneumococcal vaccine Prevenar® 13. Since 2014, over 45 million doses have been supplied to the Russian market, contributing to a 56% reduction in pneumonia-related mortality among infants in their first year of life2.
Boehringer Ingelheim
2017localization of biopharmaceutical drugs for the treatment of cardiovascular diseases
Throughout cooperation with the international company Boehringer Ingelheim, the local production of Actilyse® and Metalyse® drugs for the treatment of cardiovascular diseases were introduced to the acute phase of heart attacks and ischemic strokes treatment. The use of these drugs today is the gold standard3 of thrombolytic therapy. Petrovax is the second site in the world to produce innovative Boehringer Ingelheim thrombolytics.
ISU ABXIS
N.F. Gamaleya Center
2022
first localization of an orphan drug in Russia, including biosynthesis of the API
Petrovax, in partnership with ISU ABXIS and the N.F. Gamaleya Center of the Russian Ministry of Health, successfully completed a technology transfer project for the full-cycle production of Fabagal® (agalsidase beta) for the treatment of Fabry disease.
Since 2024, the drug has been fully produced in Russia, from biosynthesis of the API to the finished dosage form.
Adimmune
2022quadrivalent influenza vaccine production
In partnership with Taiwanese biopharmaceutical company Adimmune, Petrovax manufactures the quadrivalent influenza vaccine Grippol® Quadrivalent, using antigens certified by EMA and supplied by Adimmune.
N.F. Gamaleya Center
2023new opportunities in cancer treatment
Petrovax, in collaboration with a Chinese partner and the N.F. Gamaleya Center, is implementing a full-cycle localization project in Russia for the innovative immuno-oncology drug Areyma® (camrelizumab). This medicinal product is indicated for the treatment of several types of cancer, including nasopharyngeal carcinoma and esophageal cancer.
Areyma® was approved in Russia in 2024, with commercial supply to the domestic market commencing in May 2025.
As part of their ongoing strategic partnership, Petrovax and the N.F. Gamaleya Center are planning collaborative research projects to explore combination therapies involving mRNA-based biopharmaceuticals and Areyma®.
AryoGen Pharmed
2022Russia’s first biosimilar for osteoporosis treatment
Under a licensing agreement with AryoGen Pharmed (part of the CinnaGen Group), Petrovax has obtained Russian market authorization for Forcedeno® (denosumab). Forsedeno® is the country’s first biosimilar of the original medicinal product for targeted osteoporosis therapy.
1
2
3
